* GT Biopharma Inc GTBP.OQ GTBP.O is expected to show no
change in quarterly revenue when it reports results on August 9
(estimated).
*
* Refinitiv's mean analyst estimate for GT Biopharma Inc is
for a
loss of 10 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for GT
Biopharma Inc
is $3.5, above its last closing price of $0.27.
This summary was machine generated August 7 at 11:44 GMT. All
figures in US dollars unless otherwise stated